Aegis Capital Lifts PT on Valeant (VRX) to $180; Q4, FY13 Results Solid, M&A Still in the Mix
Tweet Send to a Friend
Aegis Capital boosts its price target on Valeant Pharmaceuticals (NYSE: VRX) from $160 up to $180, while maintaining its Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
